Menu
Switzerland’s Roche Holdings entered a merger agreement on November 26, 2024, to acquire U.S.-based Poseida Therapeutics, Inc. (PSTX) in a cash deal worth $1.5 billion.
As part of the deal, Roche will commence a tender offer to acquire all of Poseida’s outstanding shares for a price of $9.00 per share in cash at closing, representing a 214.69% premium from the stock’s last close.
The deal also includes a contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash, payable upon achievement of specified milestones.
Poseida is a biopharmaceutical company developing innovative cell and gene therapies to treat cancers, autoimmune diseases, and genetic disorders using advanced technologies and partnerships.
Roche is a global healthcare company specializing in pharmaceuticals and diagnostics, offering treatments for various conditions like cancer, anemia, autoimmune diseases, and neurological disorders. Founded in 1896 and based in Basel, Switzerland, Roche leverages strategic partnerships to develop innovative therapies, including collaborations focused on oncology research.
The proposed acquisition will strengthen Roche’s expertise in allogeneic cell therapy, building on its partnership with Poseida for CAR-T programs targeting blood cancers. It will also include Poseida’s CAR-T programs for solid tumors and autoimmune diseases, as well as its advanced genetic engineering platform and early-stage therapeutics.
“We have worked closely with Roche through our collaboration focused on hematologic malignancies, and we are excited to join Roche to work as colleagues together across our pipeline and future programs,” Kristin Yarema, president and CEO of the San Diego-based Poseida.
The deal is expected to close in the first quarter of 2025.
Roche is paying 1.83 times the sales for Poseida.
For a comprehensive understanding of this M&A transaction, please visit the Deal Metrics page here:
Deal Metrics for the acquisition of Poseida Therapeutics, Inc. (PSTX) by Roche Holdings, Inc.
The Deal Metrics page for each merger or acquisition includes:
– A spread history chart of the merger from announcement through eventual completion or failure.
– Every event as the merger progresses through the expiration of the HSR period, various regulatory approvals, shareholder votes, etc.
– News and SEC filings.
– A history of deal updates.
– And a whole lot more.
Disclaimer: Please do your own due diligence before buying or selling any securities mentioned in this article. We do not warrant the completeness or accuracy of the content or data provided in this article.
Editor’s Note: Baranjot Kaur contributed to this article